We have a history of exceptional returns on investment. In the last 15 years, thanks to our deep expertise in next-generation biomedical technologies, such as gene therapy, advanced cell therapy, nanotechnology, bionics, AI, and big data the members of the team have, in aggregate, created over $1.5Bn of net value for the investors.
Join us in shaping a world where every disease can be cured, prevented or managed.
